Drug Profile
Human skin replacement - Amarantus Bioscience
Alternative Names: Cultured skin substitute - Amarantus Bioscience; Engineered skin substitute - Amarantus Bioscience; ESS-W; PermaDermLatest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Lonza
- Developer Amarantus Bioscience Holdings
- Class Cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Burns
- No development reported Nevus
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for clinical-Phase-Unknown development in Burns(In children) in USA (Topical)
- 02 Jan 2020 Amarantus enter into a worldwide sublicense agreement for Human skin replacement to Emerald Organic Growth
- 28 Dec 2019 No recent reports of development identified for clinical-Phase-Unknown development in Nevus(In children, In infants) in USA (Topical)